Other languages Unicycive Therapeutics, Inc.

Equities

UNCY

US90466Y1038

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-10 pm EDT			5-day change	1st Jan Change
1.13 ^USD	+4.63%		+0.89%	+30.23%

Apr. 04	Piper Sandler Initiates Coverage on Unicycive Therapeutics With Overweight Rating, $9 Price Target	MT
Mar. 28	Unicycive Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Unicycive Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28
Unicycive Therapeutics Completes Patient Enrollment in Pivotal Trial for Investigational Therapy for Hyperphosphatemia	Mar. 08
Unicycive Therapeutics Completes Enrollment in Pivotal Clinical Trial for Oxylanthanum Carbonate	Mar. 07
Unicycive Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14
Unicycive Therapeutics Reaches Alignment with the Fda on Path to File New Drug Application for Oxylanthanum Carbonate	23-10-23
Unicycive Therapeutics, Inc. Announces Appointment of Sara Kenkare-Mitra to Board of Directors	23-09-06
Unicycive Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14
Unicycive Therapeutics Files Registration Statement on Behalf of Selling Stockholders	23-07-13
Top Midday Decliners	23-06-30
Unicycive Therapeutics' Shares Drop After US FDA Requested Additional Information on Lanthanum Dioxycarbonate Program	23-06-30
Wall Street Set to Open Higher Amid Slowing Inflation; Consumer Sentiment Survey Eyed	23-06-30
Top Premarket Decliners	23-06-30
Unicycive Therapeutics, Inc. Provides Regulatory Update on Lanthanum Dioxycarbonate Program	23-06-30
Unicycive Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-16
Unicycive Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-31
Unicycive Therapeutics to Raise up to $130 Million via Private Placement; Shares Soar	23-03-06
Unicycive Therapeutics Enters Into License Accord With Lotus Pharmaceutical for Renazorb in South Korea	23-02-02
Unicycive Therapeutics, Inc. Announces Exclusive License and Development Agreement with Lotus for Renazorb in the Republic of Korea	23-02-02
Unicycive Therapeutics Scraps Share Offering; Stocks Rise	22-12-29
Unicycive Therapeutics Says Renazorb's Pivotal Bioequivalence Study Achieves Primary Endpoint; Shares Rise	22-12-28

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Unicycive Therapeutics, Inc.

Equities

UNCY

US90466Y1038

Other languages

Filters